References
- Faderl S, Talpaz M, Estrov Z, et al. The biology of chronic myeloid leukemia. New Eng J Med 1999;341:164–172.
- Goldman JM, Melo JV. Chronic myeloid leukemia-advances in biology and new approaches to treatment. New Eng J Med 2003;349:1451–1464.
- Swerdlows S, Campo E, Harris NL, et al., editors. WHO classification of tumors of haematopoietic and lymphoid tissues. 4th ed. Lyon, France: IARC Press; 2008.
- Kantarijan HM, Cortes JE, O’Brien S, et al. Long-term survival benefit and improved complete cytogenetic and molecular response rates with imatinib mesylate in Philadelphia chromosome-positive chronic-phase chronic myeloid leukemia after failure of interferon-{alpha}. Blood 2004;104:1979–1988.
- Kantarjian H, Talplatz M, O’Brien S, et al. High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia. Blood 2004;103:2873–2888.
- Cortes J, Talpaz M, O’Brien S, et al. Molecular responses in patients with chronic myelogeneous leukemia in chronic phase treated with imatinib mesylate. Clin Cancer Res 2005;11:3425–3432.
- Jabbour E, Kantarjian HM, Abruzzo LV, et al. Chromosomal abnormalities in Philadelphia chromosome-negative metaphases appearing during imatinib mesylate therapy in patients with newly diagnosed chronic myeloid leukemia in chronic phase. Blood 2007;110:2991–2995.
- Mahon FX, Rea D, Guilhot J, et al. Discontinuation of imatinib in patients with chronic myeloid leukemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol 2010;11:1029–1035.
- Terre C, Eclache V, Rousselot P, et al. Report of 34 patients with clonal chromosomal abnormalities in Philadelphia-negative cells during imatinib treatment of Philadelphia-positive chronic myeloid leukemia. Leukemia 2004;18:1340–1346.
- Sun J, Yin CC, Cui W, et al. Chromosome 20q deletion: are current cytogenetic abnormality in patients with chronic myelogeneous leukemia in remission? Am J Clin Pathol 2011;135:391–397.
- Bumm T, Muller C, Al-Ali HK, et al. Emergence of clonal cytogenetic abnormalities in Ph-cells in some CML patients in cytogenetic remission to imatinib but restoration of polyclonal hematopoiesis in the majority. Blood 2003;101:1941–1949.
- Gong JG, Costanzo A, Yang HQ, et al. The tyrosine kinase c-Abl regulates p73 in apoptotic response to cisplatin-induced DNA damage. Nature 1999;399:806–809.
- Kharbanda S, Pandey P, Jin S, et al. Functional interaction between DNA-PK and c-Abl in response to DNA damage. Nature 1997;386:732–735.